MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis

Abstract

The MARS is a validated, five-parameter, WHO-independent prognostic score that defines three risk groups among patients with AdvSM and may improve up-front treatment stratification for these rare hematologic neoplasms.